VBG Group redovisade ett fortsatt svagt andra kvartal med lägre omsättning och marginaler, men vi se...
Redeye comments on Avensia’s October sales figures.
* Sales -9% and EBIT -18% vs ABGSCe * Weak utilisation in the consultant market * Expecting market s...
OXE Marine just announced a development agreement with GM Marine for the next generation of OXE outb...
Finnair’s strategy update emphasizes RASK more than CASK, which itself wasn’t a big surprise, howeve...
* Q3 was softer, but better cost control was positive * '25e-'27e sales cut by 15-22% on lower volum...
Redeye notes that Smart Eye’s Q3 was very in-line with our expectations, with only a minor deviation...
Redeye provides a note following Guard’s Q3 report, which aligned with our expectations.
Redeye updates its estimates and fair value range following BICO’s Q3 2025 report showing a return t...
Redeye updates on Better Collective after its Q3-report where leave our estimates largely unchanged ...
Redeye interviews VEF’s CEO, Dave Nangle. Dave provides an overview of the company, its track record...
Redeye updates its estimates following Surgical Science’s Q3 2025 report, which featured decent sale...
We increase 2026E-27E adj. EBIT by 6-7%, mainly owing to stronger performance in Germany – having re...
Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.
Gullberg & Jansson redovisade ökad nettoomsättning och minskad EBIT i det tredje kvartalet.
* Better-than-expected Q3 earnings, all segments up q-o-q * We raise our EBIT estimates by 4-3% for ...
Redeye comments on Isofol’s announcement that the European Patent Office (EPO) has issued an “Intent...
* Q3 a bump in the road * Estimates down given more cautious view on activity pick-up * 2025e-'27e E...
Fastighetsbolaget Trianon levererade ett starkt tredje kvartal med 33 procent högre förvaltningsresu...
Omsättningen kom in linje med Analysguidens estimat och uppgick till 7,9 (9,7) meur, varav PremierGa...
